

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 July 2024 (18.07.2024)



(10) International Publication Number
WO 2024/151833 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) C07D 417/14 (2006.01)
C07D 401/14 (2006.01) C07D 471/04 (2006.01)
C07D 405/14 (2006.01) C07D 487/04 (2006.01)
A61P 25/28 (2006.01) C07D 487/08 (2006.01)
A61K 31/4545 (2006.01) C07D 491/107 (2006.01)
A61K 31/496 (2006.01) C07D 495/08 (2006.01)
C07D 409/14 (2006.01) A61P 1/00 (2006.01)
C07D 413/14 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2024/011203

(22) International Filing Date:

11 January 2024 (11.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/479,579 12 January 2023 (12.01.2023) US

(71) Applicant: **CEREVEL THERAPEUTICS, LLC**
[US/US]; 222 Jacobs Street, Suite 200, Cambridge, MA
02141 (US).

(72) Inventors: **NGUYEN, Hanh**; 222 Jacobs Street, Suite
200, Cambridge, MA 02141 (US). **ZHANG, Xiaofeng**;
222 Jacobs Street, Suite 200, Cambridge, MA 02141 (US).
JOHNSON, Shea; 222 Jacobs Street, Suite 200, Cam-
bridge, MA 02141 (US). **ZHANG, David**; 222 Jacobs
Street, Suite 200, Cambridge, MA 02141 (US). **LIM, Jong-
won**; 222 Jacobs Street, Suite 200, Cambridge, MA 02141
(US). **PIN, Sokhom**; 222 Jacobs Street, Suite 200, Cam-
bridge, MA 02141 (US). **SARKAR, Ujjal**; 222 Jacobs
Street, Suite 200, Cambridge, MA 02141 (US). **WANG,
Minghua**; 222 Jacobs Street, Suite 200, Cambridge, MA
02141 (US). **GRAY, David**; 222 Jacobs Street, Suite 200,
Cambridge, MA 02141 (US).

(74) Agent: **DANEK, Shelley, C.**; Marshall, Gerstein & Borun
LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL
60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,


DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF



(57) Abstract: The present disclosure provides compounds of Formula I: (I) (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R¹, R², R³, R^{3a}, R⁴, R⁵, R⁶, R⁷, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

WO 2024/151833 A1